FTC blockage of Amgen's US$28 BLN takeover of HorizonPositive news for ONCY given that its acquisition does pose a conflict of interest for any acquirer like Pfizer who will be looking for an uncomplicated business deal. Pfizer's US$43 Billion proposed acquistion of Seagen is currently before the FTC, and may unfortunately result in the same "thumbs-down" decision that Amgen experienced.
"The FTC has promised to look beyond standard product overlaps when evaluating proposed biopharma transactions".
The message being sent is that smaller "bolt-on" acquisition deals between US$5 to US$15 Billion may what will be happening going forward, which is where ONCY is positioned.
https://www.fiercepharma.com/pharma/ftc-prepares-block-amgens-28b-horizon-buy-broadly-negative-move-biopharma-ma-report